Leap Therapeutics Inc.

AI Score

XX

Unlock

0.28
-0.03 (-10.94%)
At close: Apr 04, 2025, 11:05 AM

Company Description

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer.

Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers.

Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand.

The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015.

Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Leap Therapeutics Inc.
Leap Therapeutics Inc. logo
Country United States
IPO Date Jan 25, 2017
Industry Biotechnology
Sector Healthcare
Employees 52
CEO Douglas E. Onsi J.D.

Contact Details

Address:
47 Thorndike Street
Cambridge, Massachusetts
United States
Website https://www.leaptx.com

Stock Details

Ticker Symbol LPTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001509745
CUSIP Number 52187K101
ISIN Number US52187K2006
Employer ID 27-4412575
SIC Code 2834

Key Executives

Name Position
Douglas E. Onsi J.D. Chief Financial Officer, General Counsel, Treasurer & Secretary, President, Chief Executive Officer & Director
Augustine J. Lawlor Chief Operating Officer
Christine M. Granfield Vice President and Head of Regulatory Affairs & Quality
Dr. Cynthia A. Sirard M.D. Chief Medical Officer
Dr. Jason S. Baum Ph.D. Chief Scientific Officer
Mark O'Mahony Chief Manufacturing Officer

Latest SEC Filings

Date Type Title
Apr 01, 2025 4 Filing
Apr 01, 2025 4 Filing
Apr 01, 2025 4 Filing
Apr 01, 2025 4 Filing
Apr 01, 2025 4 Filing
Apr 01, 2025 4 Filing
Apr 01, 2025 4 Filing
Mar 26, 2025 S-8 Filing
Mar 26, 2025 10-K Annual Report
Mar 26, 2025 8-K Current Report